2019
DOI: 10.21320/2500-2139-2019-12-4-416-427
|View full text |Cite
|
Sign up to set email alerts
|

Heme Oxygenase-1/Ferritin in Protection of Leukemia Cells from Oxidative Stress Induced by Catalytic System “Teraphtal + Ascorbic Acid”

Abstract: Обоснование. Известно, что механизм цитотоксического действия противоопухолевого средства-каталитической системы «терафтал + аскорбиновая кислота» (ТФ+АК)-связан с образованием в клетке активных форм кислорода (ROS) и индукцией в ней окислительного стресса. Система «гемоксигеназа-1/ ферритин» (HО-1/Ft) защищает клетки от окислительного стресса. Цель. Исследовать значение системы HО-1/Ft в защите лейкозных клеток от токсического воздействия противоопухолевого средства ТФ+АК. Материалы и методы. В работе использ… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 76 publications
(61 reference statements)
0
2
0
Order By: Relevance
“…We have to mention the sodium salt of cobalt 4,5-carboxyphthalocyanine, so-called “Terafthal” (TF). The combination of Asc and TF failed phase II clinical trials in Russia. However, researchers are developing strategies to improve the therapeutic effectiveness and TF application in other fields . Sidorova and colleagues reported two times enhanced cytotoxic activity and increased ROS generation in K562/4 cells (doxorubicin resistant) after TF/Asc in combination with catalase inhibitor (3-aminotriazole) treatment .…”
Section: Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…We have to mention the sodium salt of cobalt 4,5-carboxyphthalocyanine, so-called “Terafthal” (TF). The combination of Asc and TF failed phase II clinical trials in Russia. However, researchers are developing strategies to improve the therapeutic effectiveness and TF application in other fields . Sidorova and colleagues reported two times enhanced cytotoxic activity and increased ROS generation in K562/4 cells (doxorubicin resistant) after TF/Asc in combination with catalase inhibitor (3-aminotriazole) treatment .…”
Section: Therapymentioning
confidence: 99%
“…However, researchers are developing strategies to improve the therapeutic effectiveness and TF application in other fields . Sidorova and colleagues reported two times enhanced cytotoxic activity and increased ROS generation in K562/4 cells (doxorubicin resistant) after TF/Asc in combination with catalase inhibitor (3-aminotriazole) treatment . The same research group noticed K562/4 resistant cells sensitized to cytostatic drugs and indirect expression of upregulation of heme oxygenase-1 (HO-1) and ferritin in U937 cells (human histiocytic lymphoma) after TF/Asc treatment. …”
Section: Therapymentioning
confidence: 99%